Axel Bex
阿克塞尔·贝克斯
MD, PhD
Urological Oncologist; Professor of Surgical Oncology泌尿肿瘤外科医师；外科肿瘤学教授
👥Biography 个人简介
Axel Bex, MD, PhD is a urological oncologist at the Netherlands Cancer Institute and UCL leading perioperative and surgical investigations in renal cell carcinoma. He conducted the SURTIME randomized trial that redefined the role and timing of cytoreductive nephrectomy in the era of targeted therapy, and has led efforts to evaluate neoadjuvant and adjuvant immunotherapy strategies in localized and metastatic RCC.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
SURTIME Trial: Timing of Cytoreductive Nephrectomy
Conducted the SURTIME phase III trial randomizing patients to immediate versus deferred cytoreductive nephrectomy with sunitinib, demonstrating improved overall survival with deferred nephrectomy and fundamentally changing how surgical resection is integrated in metastatic RCC management.
Neoadjuvant and Adjuvant Immunotherapy in RCC
Led prospective studies of perioperative IO therapy including neoadjuvant nivolumab and adjuvant pembrolizumab (KEYNOTE-564) in high-risk localized RCC, contributing translational correlatives defining pathological response and recurrence-free survival benefit.
Role of Surgery in Oligometastatic RCC
Advanced evidence base for metastasectomy and stereotactic ablative radiotherapy in oligometastatic RCC through prospective observational studies, informing multidisciplinary management guidelines in the IO era.
European RCC Surgical Guidelines Development
EAU (European Association of Urology) guidelines panel member for renal cell carcinoma, contributing to evidence-based recommendations on surgical management, cytoreductive nephrectomy, and perioperative systemic therapy.
Representative Works 代表性著作
Immediate versus Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic RCC (SURTIME)
European Urology (2019)
SURTIME randomized trial demonstrating improved overall survival with deferred cytoreductive nephrectomy after sunitinib induction compared with immediate surgery in metastatic RCC.
Pembrolizumab as Adjuvant Therapy for Renal-Cell Carcinoma
New England Journal of Medicine (2021)
KEYNOTE-564 phase III trial demonstrating adjuvant pembrolizumab significantly improved disease-free survival versus placebo in high-risk localized or oligometastatic clear cell RCC after nephrectomy.
EAU Guidelines on Renal Cell Carcinoma 2024
European Urology (2024)
Updated EAU clinical practice guidelines for RCC encompassing diagnosis, staging, surgical management, systemic therapy sequencing, and follow-up recommendations.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 阿克塞尔·贝克斯 的研究动态
Follow Axel Bex's research updates
留下邮箱，当我们发布与 Axel Bex（The Netherlands Cancer Institute (NKI-AVL) / University College London）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment